| 伊沙佐米治疗复发/难治多发性骨髓瘤的临床疗效 |
| |
| 引用本文： | 杨莹,刘卓刚,胡荣. 伊沙佐米治疗复发/难治多发性骨髓瘤的临床疗效[J]. 现代肿瘤医学, 2021, 0(4): 679-682. DOI: 10.3969/j.issn.1672-4992.2021.04.030 |
| |
| 作者姓名： | 杨莹 刘卓刚 胡荣 |
| |
| 作者单位： | 中国医科大学附属盛京医院血液内科，辽宁 沈阳 110022 |
| |
| 基金项目： | 辽宁省教育厅项目(编号:JC2019011)。 |
| |
| 摘 要： | 目的:评价新型口服蛋白酶体抑制剂伊沙佐米治疗复发/难治多发性骨髓瘤疗效及安全性。方法:选择2018年1月1日至2019年8月31日于中国医科大学附属盛京医院接受2个周期及以上以伊沙佐米为基础的化疗方案治疗的复发/难治多发性骨髓瘤患者。以总反应率（ORR）评价其疗效，主要包括完全缓解（CR），非常好的部分缓解（VGPR），部分缓解（PR）。同时观察药物相关不良反应。结果:共纳入27例复发/难治多发性骨髓瘤患者，ORR达63.0%,其中2例患者达到CR，4例达到VGPR，11例达到PR，中位反应时间54天。伊沙佐米治疗常见不良反应为胃肠道反应，未导致停药，经对症治疗后好转。所有患者周围神经病变未加重。结论:在此单中心回顾性研究中，伊沙佐米对复发/难治多发性骨髓瘤患者具有良好的疗效及安全性。
|
| 关 键 词： | 复发/难治多发性骨髓瘤 伊沙佐米 疗效 不良反应 |
Clinical efficacy of ixazomib in the treatment of relapse/refractory multiple myeloma |
| |
| YANG Ying,LIU Zhuogang,HU Rong. Clinical efficacy of ixazomib in the treatment of relapse/refractory multiple myeloma[J]. Journal of Modern Oncology, 2021, 0(4): 679-682. DOI: 10.3969/j.issn.1672-4992.2021.04.030 |
| |
| Authors: | YANG Ying LIU Zhuogang HU Rong |
| |
| Affiliation: | Department of Hematology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110022,China. |
| |
| Abstract: | Objective:To evaluate the efficacy and safety of a novel oral proteasome inhibitor,ixazomib,in the treatment of relapsed/refractory multiple myeloma.Methods:Patients with relapsed/refractory multiple myeloma treated with ixazomib-based chemotherapy regimens for at least 2 cycles at the department of hematology in Shengjing Hospital of China Medical University from 1 January 2018 to 31 August 2019 were selected.Overall response rate(ORR)was evaluated,including complete response(CR),very good partial response(VGPR),and partial response(PR).Adverse reactions also were observed.Results:27 patients were enrolled and ORR was 63.0%.2 patients achieved in CR.4 patients achieved in VGPR.11 patients achieved in PR,and median response time was 54 days.The common adverse reaction of ixazomib was gastrointestinal tract reaction,which did not lead to discontinuation of treatment.The peripheral neuropathy was not worsened during the treatment.Conclusion:In this single-center retrospective study,ixazomib showed good efficacy and safety in patients with relapse and refractory multiple myeloma. |
| |
| Keywords: | relapse/refractory multiple myeloma ixazomib efficacy adverse reaction |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
